Agios’ sickle cell trial falls short as drug doesn’t appear to help patient pain crisesnews2025-11-19T16:28:26+00:00November 19th, 2025|Endpoints News|
New prime editing approach could create one-size-fits-many therapiesnews2025-11-19T16:17:20+00:00November 19th, 2025|Endpoints News|
Protara trumpets small rare disease dataset in children for cell therapynews2025-11-19T15:57:02+00:00November 19th, 2025|Endpoints News|
AI biotech Profluent closes $106M raise with Jeff Bezos’ supportnews2025-11-19T15:15:30+00:00November 19th, 2025|Endpoints News|
Merck says once-daily HIV drug combo succeeds in another Phase 3news2025-11-19T14:51:35+00:00November 19th, 2025|Endpoints News|
Pfizer’s antibody pact with Nona Biosciences; Epkinly’s label expansionnews2025-11-19T14:45:01+00:00November 19th, 2025|Endpoints News|
GSK picks LTZ Therapeutics in myeloid cell engager pact worth $50M upfrontnews2025-11-19T11:58:05+00:00November 19th, 2025|Endpoints News|
Alkermes ups bid for Avadel after Lundbeck tried snatching narcolepsy biotechnews2025-11-19T11:52:06+00:00November 19th, 2025|Endpoints News|
Nabla Bio announces AI antibody model update in JAM-2news2025-11-19T10:00:53+00:00November 19th, 2025|Endpoints News|
New report suggests America must wean off China APIsnews2025-11-18T20:37:33+00:00November 18th, 2025|Endpoints News|
